Observations in patients with LN:
Histological studies have indicated:
- BLyS expression can be significantly elevated in the glomeruli of LN patients2,6
- Serum BLyS levels and increased production of intra-renal BLyS may promote renal inflammation and flares7-9
In patients with active lupus nephritis, following treatment with BENLYSTA:
- There was a decrease in serum IgG as early as Week 4, and subsequently there was an increase in serum IgG levels which was associated with decreased proteinuria
- Reductions in autoantibodies, increases in complement, and reductions in circulating total B cells and B‑cell subsets observed were consistent with those observed in patients with SLE
- The clinical relevance of these results has not been definitively established
BENLYSTA does not bind to B cells directly, but by binding to BlyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
BLyS = B-lymphocyte stimulator protein